BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Upgraded by Bank of America

Share on StockTwits

Bank of America upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a neutral rating to a buy rating in a research report released on Friday, Briefing.com Automated Import reports. They currently have $4.00 target price on the biotechnology company’s stock, down from their previous target price of $5.00.

BCRX has been the subject of a number of other reports. ValuEngine lowered shares of BioCryst Pharmaceuticals from a buy rating to a hold rating in a research note on Monday, November 4th. Needham & Company LLC reissued a hold rating on shares of BioCryst Pharmaceuticals in a research note on Wednesday, November 6th. HC Wainwright reaffirmed a buy rating and issued a $13.00 price target on shares of BioCryst Pharmaceuticals in a research note on Thursday, October 31st. BidaskClub lowered shares of BioCryst Pharmaceuticals from a sell rating to a strong sell rating in a research note on Friday, October 4th. Finally, Zacks Investment Research lowered shares of BioCryst Pharmaceuticals from a hold rating to a sell rating in a research note on Thursday, August 8th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. The company currently has an average rating of Hold and an average price target of $8.94.

Shares of BCRX traded up $0.19 during midday trading on Friday, hitting $1.89. The company had a trading volume of 167,545 shares, compared to its average volume of 2,443,415. The company’s 50 day moving average price is $2.30 and its 200 day moving average price is $3.44. The stock has a market cap of $193.27 million, a price-to-earnings ratio of -1.93 and a beta of 1.86. BioCryst Pharmaceuticals has a 52 week low of $1.38 and a 52 week high of $9.95. The company has a quick ratio of 0.94, a current ratio of 0.96 and a debt-to-equity ratio of 2.38.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03). The business had revenue of $1.78 million for the quarter, compared to the consensus estimate of $4.54 million. BioCryst Pharmaceuticals had a negative net margin of 1,129.38% and a negative return on equity of 2,511.40%. Equities analysts anticipate that BioCryst Pharmaceuticals will post -1.25 EPS for the current fiscal year.

In other news, VP Alane P. Barnes purchased 20,000 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were acquired at an average price of $1.45 per share, for a total transaction of $29,000.00. Following the completion of the acquisition, the vice president now directly owns 102,061 shares of the company’s stock, valued at $147,988.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jon P. Stonehouse purchased 50,000 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were purchased at an average price of $1.45 per share, for a total transaction of $72,500.00. Following the acquisition, the chief executive officer now directly owns 778,086 shares of the company’s stock, valued at $1,128,224.70. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 120,000 shares of company stock valued at $174,000. Company insiders own 5.20% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Bank of Montreal Can boosted its holdings in shares of BioCryst Pharmaceuticals by 921.9% during the 2nd quarter. Bank of Montreal Can now owns 10,219 shares of the biotechnology company’s stock worth $39,000 after buying an additional 9,219 shares during the period. Quantamental Technologies LLC acquired a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at $43,000. Jane Street Group LLC acquired a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at $69,000. Cubist Systematic Strategies LLC raised its stake in shares of BioCryst Pharmaceuticals by 143.6% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 27,016 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 15,924 shares in the last quarter. Finally, Quantitative Systematic Strategies LLC raised its stake in shares of BioCryst Pharmaceuticals by 297.3% in the 2nd quarter. Quantitative Systematic Strategies LLC now owns 43,590 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 32,618 shares in the last quarter. Institutional investors and hedge funds own 92.40% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Further Reading: Stock Symbols, CUSIP and Other Stock Identifiers

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analysts Set $33.00 Target Price for SpringWorks Therapeutics
Analysts Set $33.00 Target Price for SpringWorks Therapeutics
Ardelyx Inc  Given Consensus Rating of “Hold” by Analysts
Ardelyx Inc Given Consensus Rating of “Hold” by Analysts
Western Midstream Partners LP  Receives $32.25 Consensus Price Target from Analysts
Western Midstream Partners LP Receives $32.25 Consensus Price Target from Analysts
SL Green Realty Corp  Receives $93.85 Average Price Target from Brokerages
SL Green Realty Corp Receives $93.85 Average Price Target from Brokerages
HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics
HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics
Analysts Set SS&C Technologies Holdings, Inc.  Price Target at $65.91
Analysts Set SS&C Technologies Holdings, Inc. Price Target at $65.91


© 2006-2019 Ticker Report